ATHA
Athira Pharma Inc.
$7.21
-$0.30(-3.99%)
67
Overall
60
Value
75
Tech
--
Quality
Market Cap
$15.42M
Volume
74.63K
52W Range
$2.20 - $8.36
Target Price
$4.00
Company Overview
| Mkt Cap | $15.42M | Price | $7.21 |
| Volume | 74.63K | Change | -3.99% |
| P/E Ratio | -0.2 | Open | $7.33 |
| Revenue | -- | Prev Close | $7.51 |
| Net Income | $-96.9M | 52W Range | $2.20 - $8.36 |
| Div Yield | N/A | Target | $4.00 |
| Overall | 67 | Value | 60 |
| Quality | -- | Technical | 75 |
No chart data available
About Athira Pharma Inc.
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Latest News
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—12/24/25
Kirti Tak•2 days ago
Athena Gold Raises C$3.5 Million, Fully Funding Drilling Programs in Ontario
TipRanks Canadian Auto-Generated Newsdesk•7 days ago
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
William White•8 days ago
Why Is Athira Pharma Stock (ATHA) Up Today?
William White•8 days ago
Athira Pharma pivots to oncology with new licensing deal
TipRanks Auto-Generated Newsdesk•8 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ATHA | $7.21 | -4.0% | 74.63K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |